Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Boosted by Barlow Wealth Partners Inc.

Barlow Wealth Partners Inc. lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.2% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 47,572 shares of the pharmaceutical company’s stock after acquiring an additional 563 shares during the period. Vertex Pharmaceuticals makes up approximately 2.8% of Barlow Wealth Partners Inc.’s investment portfolio, making the stock its 9th largest holding. Barlow Wealth Partners Inc.’s holdings in Vertex Pharmaceuticals were worth $21,341,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. University of Texas Texas AM Investment Managment Co. acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth about $25,000. Annapolis Financial Services LLC purchased a new stake in shares of Vertex Pharmaceuticals during the first quarter worth approximately $27,000. GHP Investment Advisors Inc. purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter worth approximately $29,000. Stephens Consulting LLC purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter worth approximately $31,000. Finally, Founders Capital Management grew its holdings in Vertex Pharmaceuticals by 50.0% in the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after buying an additional 25 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 15,202 shares of the firm’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $497.00, for a total transaction of $7,555,394.00. Following the completion of the transaction, the chief executive officer now owns 106,172 shares of the company’s stock, valued at approximately $52,767,484. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Reshma Kewalramani sold 15,202 shares of Vertex Pharmaceuticals stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $497.00, for a total value of $7,555,394.00. Following the completion of the sale, the chief executive officer now owns 106,172 shares of the company’s stock, valued at $52,767,484. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $488.46, for a total value of $1,113,688.80. Following the completion of the sale, the chief marketing officer now directly owns 25,539 shares of the company’s stock, valued at approximately $12,474,779.94. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,487 shares of company stock valued at $14,657,149. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock traded up $2.17 during mid-day trading on Wednesday, reaching $461.11. 47,430 shares of the company were exchanged, compared to its average volume of 1,174,060. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26 and a current ratio of 2.52. The firm’s 50-day simple moving average is $474.88 and its two-hundred day simple moving average is $456.44. The firm has a market cap of $119.01 billion, a PE ratio of 29.78 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a twelve month low of $341.90 and a twelve month high of $510.64.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The business had revenue of $2.65 billion during the quarter, compared to analyst estimates of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the business earned $3.53 earnings per share. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post -2.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. JPMorgan Chase & Co. upped their target price on Vertex Pharmaceuticals from $505.00 to $510.00 and gave the company an “overweight” rating in a report on Monday, August 5th. HC Wainwright increased their target price on Vertex Pharmaceuticals from $500.00 to $600.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Royal Bank of Canada reduced their price target on Vertex Pharmaceuticals from $431.00 to $425.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, July 26th. Finally, Canaccord Genuity Group increased their price objective on Vertex Pharmaceuticals from $371.00 to $376.00 and gave the company a “sell” rating in a report on Wednesday, July 31st. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $486.95.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.